T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union’s Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.

ICLE 2022 |31th March – 2st April Munich

Maik Luu will present T2EVOLVE at the ICLE in Munich (31th March- 2nd April).


Helene Negre has been invited to speak during the upcoming DIA Europe 2022 on March 31 in Brussels.

SFTCG Annual Meeting | 16-18 March 2022

Helene Negre will present T2EVOLVE at annual meeting SFTCG on Thursday 17th March at 11:30 am

Cell Therapy Symposium Conference

T2EVOLVE consortium presentation at The Cell Therapy Analytics Symposium.


Now freely accessible to download.

European survey related to analytical controls of engineered T-cells

After several months of hard work and collaboration, we are pleased to launch our European survey related to analytical controls of engineered T-cells! To ensure the best success, quality, and representativity of survey’s results, we count on your participation and...

4th European CAR T-cell Meeting

Dates: February 10-12, 2022Chairs: Michael Hudecek & Ibrahim Yakoub-AghaFormat: Virtual The meeting will cover a broad range of topics including deep science and translational, clinical and commercial development in the field of CAR T. The program will bring you...

2nd Cellular Therapy & Immunobiology Working Party Workshop – 14th January 2022

T2EVOLVE is looking forward to being presented by Helen Negre at the 2nd Cellular Therapy & Immunobiology Working Party Workshop on January 14, 2022 to continue important discussions on CART.

T2Evolve at Innovative Therapies Days

On Friday, October 17, T2EVOLVE Project Leader Helen Negre discussed the European T2EVOLVE program, which aims to standardize models from both a research and patient perspective.

European survey related to analytical controls of engineered T-cells

Anyone involved in the field of engineered T-cells (academic, private, hospital, industry, CRO, CMO, etc.) can answer some questions of the survey and help us picturing current practices in Europe.


CAR T-cell therapy

Engineered T-cell therapy is a revolutionary cancer treatment where a patient’s immune cells are reprogrammed to seek and destroy cancer cells. This transformative treatment has the potential to cure cancer with a single shot. This therapy is approved and available in the EU for the treatment of leukemia and has the potential to become a blockbuster therapy for other types of cancer, as well as infectious diseases and autoimmune diseases in the future.

For additional information on CAR T-cell technology please contact UKW.


Director CAR-T Research Program, Cellular Immunotherapy for Malignant Diseases Max Eder Research Group‚ CAR T-cell engineering, Universitätsklinikum Würzburg, Germany

Prof Michael Hudecek, MD

T2EVOLVE Project Coordinator

CMC Project leader for the allogenic CAR-T program at SERVIER IRIS and EPFIA project leader T2Evolve, Suresnes Cedex, France 

Dr Hélène Negre, PhD

T2EVOLVE Scientific Director Biotechnology & Bioproduction


This project received funding from the innovative Medicines initiative 2 Joint Undertaking (JU) under grant agreement No 945393. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programe and EFPIA. More information can be found at:

Share This